DUBLIN, September 12, 2017 /PRNewswire/ --
The "Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials" report has been added to Research and Markets' offering.
The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2010, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Report scope:
- Trends in infectious vaccines dealmaking in the biopharma industry since 2010
- Analysis of infectious vaccines deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 600 infectious vaccines deal records
- Identify the most active infectious vaccine dealmakers since 2010
- The leading infectious vaccines deals by value since 2010
- Includes adjuvant deals and alliances since 2010
The available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific infectious therapy target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Infectious Vaccines dealmaking
Chapter 3 - Leading Infectious Vaccines deals
Chapter 4 - Most active Infectious Vaccines dealmakers
Chapter 5 - Infectious Vaccines contracts dealmaking directory
Chapter 6 - Infectious Vaccines dealmaking by technology type
Chapter 7 - Partnering resource center
For more information about this report visit https://www.researchandmarkets.com/research/4q5gtm/global_infectious
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article